Penumbra (PEN) Given Daily Media Sentiment Score of 0.13
Media coverage about Penumbra (NYSE:PEN) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Penumbra earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.6521365358769 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
- Discover the interventional neurology/neurovascular devices market estimated to reach USD 2,898.67 million 2021 (whatech.com)
- Thrombectomy Devices Market : Retort Pouches to Emerge Most Valued Product Variety 2025 (medgadget.com)
- Penumbra, Inc. Announces Participation at Upcoming Investor Conferences (finance.yahoo.com)
- Penumbra, Inc. breached its 50 day moving average in a Bullish Manner : PEN-US : August 24, 2017 (finance.yahoo.com)
- Penumbra, Inc. (PEN) Director Harpreet Grewal Sells 4,500 Shares (americanbankingnews.com)
PEN has been the topic of a number of research analyst reports. BidaskClub raised Penumbra from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Zacks Investment Research downgraded Penumbra from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. BMO Capital Markets reaffirmed a “buy” rating and set a $96.00 target price on shares of Penumbra in a report on Friday, June 16th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $94.00 target price on shares of Penumbra in a report on Tuesday, June 13th.
Shares of Penumbra (NYSE:PEN) opened at 85.80 on Wednesday. The stock’s 50 day moving average price is $84.80 and its 200-day moving average price is $83.20. Penumbra has a 12 month low of $56.05 and a 12 month high of $91.00. The firm has a market capitalization of $2.90 billion, a PE ratio of 579.73 and a beta of 0.10.
Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). The business had revenue of $80.60 million for the quarter, compared to analyst estimates of $77.16 million. Penumbra had a negative net margin of 2.78% and a negative return on equity of 2.58%. The firm’s revenue for the quarter was up 23.8% on a year-over-year basis. During the same quarter last year, the business posted $0.01 EPS. On average, equities analysts anticipate that Penumbra will post ($0.21) earnings per share for the current fiscal year.
In related news, Director Thomas Wilder sold 345 shares of the stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $86.10, for a total transaction of $29,704.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Daniel Donen Davis sold 32,000 shares of the stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $79.42, for a total transaction of $2,541,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 46,845 shares of company stock worth $3,794,570 in the last quarter. 22.00% of the stock is currently owned by company insiders.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Stock Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related stocks with our FREE daily email newsletter.